ACTRN12616000011482已完成1 期
Ocular safety and efficacy of a skin cream – Lauricidin® – on signs and symptoms of meibomian gland dysfunction (MGD) and dry eye
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Safety phase: 1. Age of 18 years or above
- •2. Willing and able to sign a statement of informed consent
- •3. Willing to comply with the use of the investigational product and clinical trial visit schedule
- •4. Be willing to not wear contact lenses and / or use any eye drops for at least 2 days before and during the clinical trial.
- •5. Normal ocular findings without ocular pathology.
- •Efficacy phase:
- •1. Age of 18 years or above
- •2. Willing and able to sign a statement of informed consent
- •3. Willing to comply with the use of the investigational product and clinical trial visit schedule
- •4. Be willing to not wear contact lenses and / or use any eye drops for at least 2 days before and during the clinical trial.
- •5. At least one expressible meibomian gland in each eye
- •6. Dry eye symptoms score >12 on the Ocular Surface Disease Index (OSDI) scale
排除标准
- •- Ocular pathology (Safety phase) other than dry eye/MGD (efficacy phase)
- •- Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, androgen deficiency and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome, and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
- •- Concurrent punctal occlusion;
- •- Use of or a need for concurrent category S4 and above ocular medication at enrolment and/or during the clinical trial;
- •- Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant’s ocular health / physiology either in an adverse or beneficial manner at enrolment and/or during the clinical trial e.g. hormone replacement therapy or anti-androgen therapy;
- •- Eye surgery within 12 weeks immediately prior to enrolment for this trial.
- •- Previous corneal refractive surgery;
- •- Known allergy or intolerance to ingredients in any of the diagnostic products used during the clinical trial;
- •- Currently enrolled in another clinical trial;
- •- Current use of antibiotics;
- •- Pregnancy*.
- •The Investigator may, at his / her discretion, exclude anyone who he /she believes may not be able to fulfil the clinical trial requirements or it is believed to be in the participant’s best interests.
- •*Formal testing of pregnancy is not required. A participant’s verbal report is sufficient.
研究者
相似试验
已完成
3 期
Consideration of the effect of Artemisia absinthium on eye darknessIRCT20190413043259N1Tehran University of Medical Sciences60
已完成
不适用
nder Eye Cream study for dark circleCTRI/2020/12/029753MCaffeine42
已完成
不适用
Anti-wrinkle effect of eye care creamHealthy adult femaleJPRN-UMIN000037011Japan Clinical Trial Association16
已完成
不适用
To evaluate opthalmological and dermatological safety of skin care productsCTRI/2021/11/038306SERY COSMETICS LLP30
已完成
不适用
Comparing the effectiveness of simple eye ointment with moisture chamber over the eye and eyelid taping to prevent ocular surface disorders in critically ill patientsCondition 1: Corneal surface disorders. Condition 2: Chemosis.Keratitis, unspecified) Other conjunctival vascular disorders and cysts,(oedema)IRCT201109225426N3Kerman University of Medical Sciences Research Center120